Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 16/20 | 0.50 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351324 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL22422289 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL11491220 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL11870539 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL542497 | 0.97 | PDE7A (0.47) | PDE7APDE7BCRBN | |
| SCHEMBL630549 | 0.92 | CRBN (0.43) | PDE7APDE7BCRBN | |
| SCHEMBL8775591 | 0.87 | — | — | |
| SCHEMBL23039345 | 0.86 | PDE7A (0.41) | PDE7APDE7BCRBN | |
| SCHEMBL4458582 | 0.81 | PDE7A (0.43) | PDE7APDE7B | |
| SCHEMBL31721361 | 0.81 | CRBN (0.40) | PDE7ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3101018-A1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma L.P. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
| EP-2076506-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | Purdue Pharma L.P. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-4189587-A | CORROSION RESISTANCE | CIBA-GEIGY CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | PDE7A 724/4885PDE7B 996/4885CRBN 4832/4885 |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | PDE7A 829/4885PDE7B 2745/4885CRBN 3657/4885 |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | PDE7A 656/4885PDE7B 1729/4885CRBN 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.